Training breast cancer survivors to better recognize bodily signals to reduce anxiety
ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors
This study is testing a new training program to help breast cancer survivors better understand their body's signals to see if it can reduce their anxiety after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | King's College London Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT06954532 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and acceptability of a novel interoceptive training approach called ADIE Therapy for breast cancer survivors experiencing anxiety. ADIE Therapy focuses on enhancing the ability to recognize and interpret internal bodily signals, which may help alleviate anxiety and somatic symptoms that persist after cancer treatment. The study employs a mixed-methods approach to assess how well this therapy is received and its practicality for individuals who have completed treatment for primary breast cancer. Participants will engage in biofeedback-based tasks aimed at improving their interoceptive awareness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have completed treatment for primary breast cancer and reside in the UK.
Not a fit: Patients currently undergoing treatment for breast cancer or those with certain cardiac conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly reduce anxiety and improve the quality of life for breast cancer survivors.
How similar studies have performed: While ADIE Therapy has shown promise in non-cancer populations, its application in breast cancer survivors is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or older * Residing in the UK and able to travel into London * Can read and write in English * Have had a diagnosis of Primary Breast Cancer * Have completed active, hospital-based treatment for primary breast cancer (Stages 1, 2 or 3; this refers to radiotherapy, surgery, or chemotherapy) 6 months - 10 years previously (this does not apply to ongoing endocrine (hormone) therapy) Exclusion Criteria: * Currently taking medication for cardiac arrhythmia (e.g., beta blockers) * Currently in active treatment for breast cancer and/or other types of cancer * Currently pregnant
Where this trial is running
London
- King's College London — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Lauren C. Heathcote, PhD — King's College London
- Study coordinator: Lauren C. Heathcote, PhD
- Email: lauren.heathcote@kcl.ac.uk
- Phone: 2071882597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.